Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, Kalofonos HP, Aravantinos G, Tsoutsos D, Panagiotou P, Frangia K, Petrakopoulou T, Pectasides D; Hellenic Coperative Oncology Group. Gogas H, et al. Among authors: ioannovich j. Anticancer Res. 2004 May-Jun;24(3b):1947-52. Anticancer Res. 2004. PMID: 15274382 Free article. Clinical Trial.
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Gogas H, et al. Among authors: ioannovich j. N Engl J Med. 2006 Feb 16;354(7):709-18. doi: 10.1056/NEJMoa053007. N Engl J Med. 2006. PMID: 16481638 Free article. Clinical Trial.
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, Kalofonos H, Fountzilas G, Panagiotou P, Kokkalis G, Papadopoulos O, Castana O, Papadopoulos S, Stavrinidis E, Vourli G, Ioannovich J, Gogas H. Pectasides D, et al. Among authors: ioannovich j. J Clin Oncol. 2009 Feb 20;27(6):939-44. doi: 10.1200/JCO.2008.16.3121. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139440 Clinical Trial.
Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H, Bafaloukos D, Aravantinos G, Fountzilas G, Tsoutsos D, Panagiotou P, Frangia K, Kalofonos HP, Briasoulis E, Castana O, Polyzos A, Pectasides D, Ioannovich J; Hellenic Cooperative Oncology Group. Gogas H, et al. Among authors: ioannovich j. Cancer Invest. 2004;22(6):832-9. doi: 10.1081/cnv-200039630. Cancer Invest. 2004. PMID: 15641480 Clinical Trial.
Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center.
Tsoutsos D, Papadopoulos S, Kehagias G, Mara A, Kyriopoulou E, Karonidis A, Spiliopoulos K, Mpalitsaris E, Karapiperis G, Panayotou P, Papaliodi E, Choreftaki T, Papaxoinis G, Benopoulou O, Ioannovich J, Gogas H. Tsoutsos D, et al. Among authors: ioannovich j. Melanoma Res. 2018 Aug;28(4):348-358. doi: 10.1097/CMR.0000000000000456. Melanoma Res. 2018. PMID: 29762190
42 results